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Abstract  
 
Background. Influenza vaccine immunogenicity is suboptimal in immunocompromised 
patients. However, there are limited data on the interplay of T- and B- cell responses to 
vaccination with simultaneous immunosuppression.  
Methods. We collected peripheral blood mononuclear cells from transplant recipients pre 
and one-month post seasonal influenza vaccination. Pre- and post-vaccination, H1N1-
specific T- and B-cell activation were quantified using flow cytometry. We further 
developed a mathematical model using T- and B-cell markers, and mycophenolate 
mofetil (MMF) dosage.  
Results. In the 47 patients analyzed, seroconversion to H1N1-antigen was 34%. H1N1-
specific IL-4-producing CD4+ T-cell frequencies significantly increased after vaccination 
in 53% of the patients. Pre-vaccination expression of H1N1-induced HLA-DR and CD86 
on B-cells was high in patients that seroconverted. Seroconversion against H1N1 was 
strongly associated with HLA-DR-expression on B-cells, which was dependent on the 
increase of H1N1-specific IL-4+CD4+ T-cells pre-to-post vaccine (R2=0.35). High doses 
of MMF ≥2g/d led to lower seroconversion rates, lower increase of H1N1-specific IL-
4+CD4+ T-cells and reduced HLA-DR-expression on B-cells. The mathematical model 
incorporating a MMF-inhibited positive feedback loop between H1N1-specific IL-
4+CD4+ T-cells and HLA-DR-expression on B-cells captured seroconversion with high 
specificity.  
Conclusions. Seroconversion is associated with influenza-specific Th2 and B-cell 
activation and appears to be modulated by MMF. 
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Introduction: 
Infection with influenza viruses in organ transplant recipients is associated with greater 
risk of hospitalization and mortality [1, 2]. The primary means to prevent influenza in this 
population is through annual influenza vaccination [3]. In immunogenicity studies, 
transplant recipients show suboptimal seroconversion rates against influenza [4, 5]. 
Factors associated with reduced humoral immunity include the use of mycophenolate 
mofetil (MMF), vaccination within the first year after transplantation, and receipt of a 
lung transplant [4, 6-9]. In particular, MMF dosage above 2g/day is a strong predictor of 
vaccine failure [9-11].  
Protective immunity against influenza involves a multitude of interactions between the 
innate and adaptive immune system [12, 13]. Neutralizing antibody against influenza is 
well-known to protect against infection [14]. Seroprotection and seroconversion are 
frequently used as surrogates of vaccine protection in the general population. Although 
neutralizing antibodies play an important role in prevention of infection, influenza-
specific T-cell responses add to the protection and may be cross-reactive to provide broad 
protection against drifted strains of influenza [15]. While Th1 and cytotoxic T-cell 
response clear viral infected cells, Th2 responses stimulate antibody production. The type 
of immunity stimulated by influenza vaccination likely defines the degree of protection. 
Previous studies of cellular immunity against influenza after transplantation have focused 
on interferon-gamma (IFN-γ, a Th1 cytokine) production from T-cells and have not 
shown an association with humoral immunity [16, 17]. Limited data exist for the 
transplant population and the interaction of influenza-specific Th2-cells and B-cells.  
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We hypothesized that influenza vaccine immunogenicity after transplantation is likely to 
be related to the interplay of Th2 and B-cells and that immunosuppression is an important 
regulator. To test these hypotheses, we analyzed humoral and cellular immunity in a 
cohort of solid organ transplant patients and healthy controls that were given influenza 
vaccine. Peripheral blood mononuclear cells were stimulated with influenza-antigen and 
underwent flow-cytometric analysis for intracellular IFN-γ as a marker for Th1-response, 
IL-4 as a marker of Th2-response and HLA-DR and CD86-expression as activation 
markers for B-cell response. In addition, we developed a computational model to 
investigate the influence of MMF on the interplay of T- and B-cells.  
 
Materials and Methods 
Patient population 
From the original trial comparing intradermal vs. intramuscular influenza vaccine, adult 
solid organ transplant patients were randomly selected to participate in a cellular 
immunity substudy (n=47) [6]. No significant differences in humoral immunity between 
intradermal and intramuscular vaccine were seen [6]. All patients received non-
adjuvanted 2010-11 influenza vaccine containing the following influenza strains: 
A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 either in 
a high-dose (18 µg per antigen) intradermal (Intanza, Sanofi-Pasteur) or a standard dose 
(15 µg per antigen) intramuscular preparation (Vaxigrip, Sanofi-Pasteur). Patients had 
whole blood collected pre-vaccination and 4 weeks post-vaccination.  
Eleven healthy volunteers (HV) were separately recruited, and received standard 
intramuscular vaccination with the 2011-12 vaccine (Vaxigrip, Sanofi-Pasteur). The 
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vaccine viruses in the 2011-12 vaccine were identical to those in the 2010-11 vaccine. 
The study protocols were approved through the institutional research ethics board and 
written informed consent was obtained from all participants. 
 
Humoral Response to Vaccine 
Sera underwent hemagglutination inhibition assay (HAI) for the H1N1-antigen contained 
in the vaccine as previously described [18]. Definitions of vaccine immunogenicity were 
based on recommendations for annual licensure of influenza vaccine (European 
Medicines Agency, document: CHMP/VWP/164653/2005). Seroconversion was defined 
as a ≥4-fold rise in titer from pre-vaccination and a post-vaccine titer ≥1:40. However, if 
pre-vaccination antibodies are present, the definition of ‘seroconversion’ may also 
represent a booster effect or a cross-reactive immune response. Seroprotection was 
defined as a titer of ≥1:40. 
 
PBMC isolation and stimulation 
Peripheral blood mononuclear cells were isolated from whole blood using a Ficoll-based 
method and cryopreserved until use.  PBMCs were stimulated with formalin inactivated, 
partially purified A/California/7/2009 (H1N1) (NIBSC, NYMC-X179A, UK), the same 
strain as in the vaccine. A final concentration of 0.3g/mL was used to stimulate cells for 
16h at 5% CO2. Cells were stimulated in RPMI containing 5% fetal calf serum, and 1% 
Glutamax (R5, all Sigma) at a concentration of 2 x 105 cells per well. 
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Flow cytometry 
Experiments were performed on a FACSCanto II (BD, Franklin Lakes, NJ) and analyzed 
with FlowJo v 10.0.5 (TreeStar, Ashland, OR). Figure S1 shows the overall gating 
strategy (Figure S1). Media alone served as negative control and was subtracted from 
samples stimulated with influenza-antigen. LIVE/DEAD® staining was performed (near-
IR; Invitrogen). Markers for identifying T-cell subsets were CD3 (Pacific Blue), CD4 
(PE-Cy7), and CD8 (characterized as the CD4 negative gate). Intracellular cytokine 
staining was performed according to previously published protocols [19]. IFN-γ (Alexa 
Fluor 488) and IL-4 (APC) were used as key representatives for Th1 and Th2 cytokine 
production respectively. All reagents including perm and fixation buffers and antibodies 
were from eBioscience (San Diego, Ca). Isotype controls have previously been used to 
establish the assays. 
Markers for B-cell subsets were CD20 (Alexa Fluor 488) and CD27 (PE), where naïve B-
cells are CD20+CD27- and memory B-cells are CD20+CD27+. HLA-DR (Pacific Blue) 
and CD86 (APC) served as activation markers (Biolegend – San Diego, CA - or 
eBioscience). 
 
Cytokine profile 
Cell-free supernatants from H1N1-stimulated PBMCs were collected after 24h and used 
for cytokine analysis. A 17-plex luminex-based cytokine profiling kit was used (Eve 
Technologies, Calgary, Canada): Fractalkine, IFN-, IFN-, GRO, MCP-3, IL-13, 
sCD40-L, IL-9, IL-1, IL-2, IL-4, IL-5, IL-6, IP-10, MCP-1, MIP-1, and TNF-.  
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Cytokine profile analysis 
GeneSpring GX version 12 (Agilent Technologies, Santa Clara, CA) was used for cluster 
and principal component analysis (PCA) of the cytokines measured in H1N1-stimulated 
PBMCs. Non-stimulated samples were subtracted from stimulated PBMCs. Percentile 
shift was used as normalization algorithm and baseline transformation was performed to 
the median of all samples. Hierarchical clustering was done using Euclidean as similarity 
measure and Centroid as linkage rule. PCA was used to detect major trends in the 
experimental conditions. ANOVA cluster analysis was used to compare antibody 
response clusters. 
 
Mathematical model 
We constructed a phenomenological ordinary differential equation (ODE) model as 
described in detail in Supplementary Information and Table S1. Numerical 
simulations were performed in MATLAB (R2014a, The Mathworks, Natick, MA), with 
the CVODE ODE integrator from the sundialsTB toolbox [20]. Parameter estimation was 
performed using the MEIGO toolbox [21], and confidence intervals were determined 
using the HYPERSPACE toolbox [22]. 
 
Statistical analysis 
Statistical analyses were performed using SPSS Statistics (version 20.0, IBM, Chicago, 
IL) and GraphPad Prism (version 4.0, GraphPad Software, La Jolla, CA). Data are shown 
with median and inter-quartile ranges. Categorical variables were analyzed using a Chi-
Square (Chi2) test. Continuous non-normal distributed data (Shapiro Wilk test) were 
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analyzed using a Mann-Whitney U test (MWU) or if paired using a Wilcoxon matched 
pairs rank test (WCR). All tests were two-tailed. 
 
 
Results: 
Humoral immunity is reduced by mycophenolate mofetil 
We enrolled 51 transplant recipients for cellular immune assays. Of these, two were lost 
to follow-up and two patients did not have sufficient T-cells in the post-vac ination 
sample for analysis. Of the remaining 47 patients, the median age was 53.4 years (range 
21-77) and most patients (51%) were kidney transplant recipients (Table 1). The majority 
of patients were on a combination of immunosuppressing drugs. All transplant patients 
had received prior year influenza vaccine and did not previously have microbiologically-
proven influenza infection.  By HAI, the pre-vaccine seroprotection rate to influenza 
A/H1N1 was 46.8% (22/47). Post-vaccine the seroprotection rate was 68.1% (32/47) to 
influenza A/H1N1, but only 16/47 (34%) demonstrated seroconversion. Transplant 
recipients on ≥2g/d MMF showed significantly lower geometric mean antibody titers 
than those on <2g/d (GMT 43.1 vs 128.4; p=0.034). The median trough level of 
tacrolimus and cyclosporine in patients on ≥2g/d MMF was not statistically significant 
different compared to those on <2g/d (7.85µg/mL vs. 6.5µg/mL; 68µg/mL vs. 187µg/mL 
respectively).  In lung transplant recipients vs. non-lung transplant recipients 
seroconversion rates were not significantly different for H1N1, p=0.353.  
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H1N1-specific IL4-producing CD4+ T-cells, but not IFNγ-producing CD4+ or CD8+ 
T-cells are associated with seroconversion after H1N1 vaccination 
In transplant patients, H1N1-specific IL-4+CD4+ T-cells showed a significant increase 
pre- to post-vaccination (median 0.32% to 0.78%; p=0.04) (Figure S2A). Of the 47 
patients, 25/47 (53.2%) had an increase in H1N1-specific IL-4+CD4+ T-cells post-
vaccination. This increase was driven primarily by seroconverting patients. We observed 
a significant induction of post-vaccination IL-4+CD4+ T-cells only in persons with 
seroconversion (Figure 1A). Patients who were receiving ≥2g/d MMF had a lower, non-
significant increase in their IL-4+CD4+ T-cells, whereas those on lower MMF doses had 
a significant increase (p=0.035; Figure 1B). The frequency of H1N1-specific 
IFN+CD4+ and IFN+CD8+ T-cells did not show a significant increase post-
vaccination (Figure S2B). IFN+ T-cell frequencies were not significantly associated 
with seroconversion and did not show any association with MMF dose (data not shown). 
However, the pre-to-post vaccination ratio of IL-4+CD4+ to IFN+CD4+ T-cells was 
significantly higher in patients with seroconversion, suggesting differences in expansion 
dynamics of T-cell subsets (median 1.7-fold to 1.0-fold, p=0.047). Lung-transplant 
recipients showed a median pre-vaccination IL4+CD4+ T-cell frequency of 0.33% vs. 
0.35% in non-lung transplants (p=0.26). Similarly, post-vaccination IL4+CD4+ T-cell 
frequency was 0.62% vs. 0.86% (p=0.58) in lung transplant vs. other transplant types. 
 
Expression levels of H1N1-induced CD86 and HLA-DR on B-cells predicts 
seroconversion following H1N1 vaccination 
We measured B-cell activation markers after stimulation with H1N1-antigen. In 
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transplant recipients, HLA-DR-expression in all B-cells (as measured by mean 
fluorescence intensity) did not significantly increase after vaccination. However, baseline 
HLA-DR-expression was significantly greater prior to vaccination in patients that 
eventually went on to seroconversion. This was true for both the naïve B-cells subset 
(CD20+CD27-, p=0.0002) as well as memory B-cells (CD20+CD27+, p=0.0003) 
(Figure 2A). Table 2 provides an overview comparison of patients in different subsets 
(Table 2).  
H1N1-inducible CD86-expression did not significantly change after vaccination. 
However, CD86-expression was significantly greater in patients that seroconverted 
specifically in the naïve B-cell subset (Figure 2B). In addition, post-vaccination, patients 
receiving ≥2g/d MMF had reduced H1N1-stimulated CD86-expression on naïve B-cells 
compared to those receiving <2g/d (p=0.05) (Figure 2C). Pre-vaccination (baseline) 
levels of CD86- and HLA-DR-expression were predictors of seroconversion (AUC for 
HLA-DR 0.843). For HLA-DR (CD86) expression, the highest sensitivity and specificity 
were 76.5% (70.6%) and 84.6% (76.9%) , respectively (Table 3). We further explored 
the role of IL-4+CD4+ T-cells on B-cell activation, a process that is partially regulated by 
T-helper cells and Th2-cytokines such as IL-4. In patients who seroconverted, the 
increase in H1N1-specific IL-4+CD4+ T-cells post-vaccination was directly correlated to 
HLA-DR-expression on B-cells (p=0.019; Figure 2D). 
 
H1N1-induced cytokine profile pattern reflects seroconversion to influenza in 
transplant patients 
Cytokine profiles were measured in supernatants collected from post-vaccination samples 
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in which PBMCs were stimulated with H1N1-antigen. We explored the differences in 
cytokine profiles with and without seroconversion using a heat-map and principal 
component analysis (Figure 3A). Based on the expression profile of 28 immune markers 
(including 17 cytokines), the cluster analysis indicated three predominant groups. These 
three clusters represent: (1) patients without seroconversion but with seroprotection, (2) 
patients without seroconversion or seroprotection (non-responders), and (3) patients with 
seroconversion and seroprotection. Figure 3B shows the mean expression of each marker 
in the three clusters. Cluster (1) showed a relatively high expression of Th2-cytokines, 
and low expression of Th1-cytokines; this was associated with high pre- and post-vaccine 
HAI antibody titers to H1N1 even though these patients did not seroconvert. Cluster (3) 
identified a population of patients with a significant increase in HAI titers after 
vaccination; in particular the B-cell activation markers were significantly upregulated in 
these patients. A two dimensional PCA indicated that HLA-DR-expression and Th2-
cytokines may be responsible for this clustering (data not shown). 
 
A phenomenological mathematical model predicts vaccine response 
We developed a dynamic mathematical model of the following structure (Figure 4A): An 
assumption for the model was that IL4-producing CD4+ T cells activate B cells and 
upregulate HLA-DR expression in a positive feedback loop. This interaction results in 
antibody production from B-cells. MMF serves as a dose-dependent inhibitor of this 
feedback loop. The model describes the evolution over time of the percentage of H1N1-
specific IL-4+CD4+ T-cells, HLA-DR-expression on B-cells, and serum antibody (HAI) 
titers as a result of H1N1 vaccination. 
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Using this model, day 30 (post-vaccination) values for each variable as well as these 
variables’ dynamics after vaccination can be predicted in patients who seroconverted vs. 
those that did not seroconvert. The model was calibrated to conservatively predict 
seroconversion, and based on our current data it achieves a sensitivity of 70% and 
specificity of 100% as determined by leave-one-out cross validation (for details see 
Supplement Information and for estimated model parameter Table S1). Figure 4B 
shows the predicted dynamics of the IL-4+CD4+ T-cell frequency, HLA-DR-expression 
on B-cells, and H1N1 antibody HAI titer starting from patient baseline values at day 0 
with modulation by actual MMF dosages. These simulation results illustrate a strong 
dependency of seroconversion on sufficient pre-vaccination HLA-DR-expression levels. 
Simulations with hypothetical low (Figure 4C) and high (Figure 4D) daily MMF 
demonstrate an inhibitory effect of MMF that is especially pronounced at high dosages (≥ 
2g/d MMF). 
 
Healthy Volunteer Response to Vaccine 
Humoral and cellular vaccine responses were also evaluated in 11 healthy volunteers. 
Healthy volunteers were significantly younger than the transplant recipients and they did 
not receive immunosuppressive drugs. All healthy volunteers had received influenza 
vaccine in prior years and did not have a history of microbiologically-proven influenza 
infection. A significant increase in HAI titers to H1N1 after immunization (GMT 66 to 
345; p=0.009) was observed (100% seroprotection and seroconversion to H1N1). 
Compared to transplant patients, geometric mean titers were significantly higher in 
healthy controls (83 vs. 345; p=0.016). Similar to transplant recipients, healthy volunteers 
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also showed a significant increase in the frequency of H1N1-specific IL-4+CD4+ T-cells 
after vaccination. However, unlike transplant recipients, healthy volunteers did show an 
increase in IFN+CD4+ T-cells post-vaccination (Figure S2B). H1N1-induced B-cell 
activation markers were high in healthy volunteers and were similar to transplant 
recipients (data not shown); healthy volunteers also had no significant changes in HLA-
DR- and CD86-expression pre- to post-vaccination (data not shown). The post-
vaccination cytokine profile showed that healthy controls had significantly greater levels 
of Fractalkine, IFN-, MCP-3, IL-1, IL-6, and MIP-1 (Figure S2C). The results of the 
cytokine profile are shown in Table S2. These findings should be interpreted in the 
context of the significantly younger age of the healthy volunteers compared to the 
transplant recipients. 
 
Discussion 
We performed a detailed analysis of H1N1-induced B- and T-cell responses to assess 
factors associated with successful seroconversion after influenza vaccination in the organ 
transplant population. We show that Th2-cytokines are associated with H1N1-induced B-
cell activation in terms of HLA-DR (antigen presentation) and CD86 (co-stimulatory 
signaling) expression, as well as antibody secretion. MMF reduced IL-4+CD4+ T-cell 
frequencies and B-cell activation.  The type of graft (lung vs. nonlung transplant) did not 
have an effect on T-cell responses. We employed several analytical techniques to 
formulate sensitive and specific predictive models to discriminate vaccine responders 
from non-responders. 
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The influenza vaccine stimulates the Th1- and Th2-pathway in order for B-cell 
differentiation to occur [23]. One of our key findings was the increase in H1N1-specific 
IL-4+CD4+ T-cells after vaccination. IL-4 is involved in humoral immunity and 
previously has not been explored in the context of vaccination of transplant recipients. 
IL-4 (originally termed B-cell stimulatory factor 1) is a cytokine produced by Th2-cells 
and has been shown to increase HLA-DR-expression on resting B-cells, thereby 
increasing production of IgG [24, 25]. Th2-responses have also been shown to be 
important in mice immunized with a universal influenza vaccine [26]. 
 
We did not observe a significant rise in IFNγ+CD8+ T-cell frequency after vaccination in 
transplant recipients, contrary to that seen in the healthy volunteer cohort. The frequency 
of H1N1-specific IFNγ+CD4+ and IFNγ+CD8 T-cells was consistent with previous 
studies of influenza vaccine [27]. These results were also similar to results shown by 
Cowan et al. who showed a significantly greater increase in IFNγ-responses in healthy 
controls compared to kidney transplant patients [28]. Another study in lung transplant 
recipients also did not show an increase in influenza-vaccine related IFNγ post-influenza 
vaccination [17]. Previous studies in transplant recipients have not found a relationship 
between IFNγ and humoral responses. For example, in a kidney transplant cohort, 
although an increase in IFNγ was seen post-vaccination, this was not associated with 
humoral responses [16]. The study by Cowan et al. also did not show a correlation 
between IFNγ T-cell responses and influenza-specific IgG responses [28]. Virus-specific 
CD8+ T-cells typically recognize peptides derived from internal components of the virus 
[29]. Thus, during influenza replication, cytotoxic T-cells could respond to a broader 
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spectrum of possible expressed epitopes and proteins in comparison to strain-specific 
antibodies to the viral HA and NA glycoproteins [30]. However, inactive vaccines do not 
replicate and therefore they contain only a limited spectrum of proteins, namely HA and 
NA glycoproteins; the induced CD8+ T-cell response may not directly correlate with an 
antibody response. Nevertheless, if an IFN-γ response develops, it could promote the 
induction of HA-specific neutralizing antibodies and may in fact help with broadening 
responses to heterologous influenza viruses [31, 32]. 
 
In the non-transplant literature, the ratio of Th2:Th1-cytokines has been suggested to be 
associated with vaccine responses in the elderly. Similar to our study, McElhaney et al. 
measured IL-10 as a marker of Th2 responses and showed that there was a significant rise 
in IL-10 post-vaccination in PBMCs of elderly persons stimulated with H1N1 [33]. In our 
cohort we observed a significant increase of IL-4-producing CD4+ T-cells in patients 
with seroconversion. In addition, our cytokine profile indicated significant differences in 
Th2 cytokines in patients with seroconversion and seroprotection compared to non-
responding patients. 
 
We also explored B-cell immunity using HLA-DR and CD86 as markers of activation. 
HLA-DR acts as a ligand for the T-cell receptor resulting in antigen presentation and 
further stimulation of T-cells. Additionally, CD86 acts as a co-stimulatory molecule on 
B-cells and interacts with CD28 on T-cells [34]. These markers have not previously been 
explored in the context of immunization of organ transplant recipients. The pre-
vaccination expression of these markers was high in patients that seroconverted, 
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suggesting a role for these markers in prediction of seroconversion. Indeed, a ROC curve 
analysis showed that baseline HLA-DR and CD86-expression had high sensitivity and 
specificity in predicting seroconversion. The high responsiveness of memory B-cell 
subsets prior to vaccination may be partially explained by prior illness or previous 
vaccine. All transplant recipients and healthy volunteers had previously received 
influenza vaccine. 
 
General effects on IgG serum concentration in transplant recipients treated with MMF 
have been previously described [35]. Several studies have now shown that high doses of 
MMF reduce the immunogenicity of influenza vaccination [9-11]. Our cohort also had 
reduced responses by HAI in patients receiving doses of ≥2g/d. MMF and MPA have 
been shown to inhibit B-cell activation and proliferation and plasma cell formation [36, 
37]. Our study provides insight into a potential mechanism by which this occurs. We 
found that high doses of MMF had a deleterious impact on IL-4+CD4+ T-cell 
frequencies and was associated with reduced HLA-DR-expression on B-cells. Our results 
are consistent with a previous study which showed a dose-dependent reduction of HLA-
DR-expression on B cells with increasing mycophenolate [38]. In addition, the ODE 
model predicts high, sustained antibody titers in most patients who seroconverted, and 
low antibody titers (with possibly high transient titers) in patients who did not. Without 
MMF, the model predicts that most patients that did not seroconvert in the study would 
develop high antibody titers at day 30, and with a hypothetical 3g/d MMF, the model 
predicts that none of the patients seroconvert. Large uncertainties in estimated model 
parameters, however, indicate that more data (patients and time points) and possibly 
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model extensions will be required to obtain final conclusions on the modeling approach’s 
predictive power. 
 
Our study has some limitations. Almost all our patients and healthy volunteers had been 
previously vaccinated and this may have influenced the response seen. We only used 
certain signature cytokines for the Th1 and Th2 response. It is possible that othe  
cytokines may behave differently. In addition, although the trivalent influenza vaccine 
contains two A strains and one B strain, we used influenza A/H1N1 as a model for 
vaccine responses. It is possible that other strains of influenza such as A/H3N2 and B 
strains induce differing Th1 and Th2 profiles. We also had different organ types 
represented in our population, though this allowed us to provide a broad overview of 
cellular immunity to vaccine in the transplant population. An important point is that our 
healthy control group was also significantly younger compared to the transplant cohort. It 
has been well described that aging is an important factor for reduced humoral responses 
[33], and the comparative immunologic responses between transplant and healthy 
individuals should be interpreted in this context.  
 
In summary, Th2 responses appear to be key regulators of influenza vaccine response in 
transplant patients. B-cell activation markers prior to immunization have the potential to 
predict future humoral responses to vaccine.  Mycophenolate mofetil is a key regulator of 
these responses at the cellular level. Tailoring immunosuppression to influence the 
vaccine response via upregulation of a Th2 cytokine profile may be a future strategy to 
improve outcomes of vaccination. 
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Figure Legends 
 
Figure 1. H1N1-specific IL-4+CD4+ T-cell dynamics during vaccination 
(A) Frequency of H1N1-specific IL-4+CD4+ T-cells in patients that seroconverted vs. 
those who showed no seroconversion to influenza A/H1N1 (n=15 vs. 32).  Patients that 
seroconverted had a greater rise in the frequency of IL-4+CD4+ T-cells after vaccination 
(p=0.04). 
(B) Frequency of H1N1-specific IL-4+CD4+ T-cells in patients who received ≥2g daily 
dose of MMF vs. those who received <2g daily dose of MMF (n=19 vs. 28).  
 
Figure 2: H1N1-induced B-cell activation during vaccination. 
The background (non-stimulated) expression of HLA DR and CD86 was subtracted. The 
median background for HLA DR was 95.9 A.U., and for CD86 43.7 A.U. (also see Table 
2) 
(A) Expression of H1N1-induced HLA-DR-expression on naïve and memory B-cells 
prior to vaccination is greater in patients that seroconverted vs. those who showed no 
seroconversion to influenza A/H1N1 (n=15 vs. 32). Bars indicate median values, 
whiskers show the interquartile range. Mann-Whitney U testing was used to determine 
significant differences.   
(B) Expression of H1N1-induced CD86-expression on naïve and memory B-cells is 
greater in patients that seroconverted vs. those who showed no seroconversion to 
influenza A/H1N1 (n=15 vs. 32). Bars indicate median values, whiskers show the 
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interquartile range. Mann-Whitney U testing was used to determine significant 
differences.   
(C) Expression of H1N1-induced CD86-expression on naïve B-cells post-vaccination 
based on MMF dose.  Patients receiving ≥2g MMF daily dose had significantly less 
expression of CD86. Bars indicate median values, whiskers show the interquartile range. 
Mann-Whitney U testing was used to determine significant differences.   
(D) Regression analysis of fold-change in IL-4+ T-cell frequencies and their impact on 
HLA-DR-expression on B-cells in patients with seroconversion (n=15). 
 
FIGURE 3: H1N1-induced cytokine profile. 
(A) Heatmap of cytokines, antibody titers and B-cell activation markers in H1N1-
stimulated PBMCs of the total post-vaccine transplant cohort. Blue represents 
seroconversion (n=15) and red represents no seroconversion (n=28, for 4 samples no 
cytokine profile was available). Non-stimulated background samples were subtracted 
prior to normalization algorithm. Relative changes of a marker are indicated by change of 
color code (blue, max 5.8 fold down-regulation; red, max 5.8 up-regulation). Markers 
analyzed (top to bottom): FRAK, IL13, IL9, IL5, CD4 IFNγ, CD4 IL-4, IL-4, mB CD69, 
IL1β, GRO, sCD40L, H1N1 Antibody titer, IFNα, IL2, IFNγ, TNFα, IL6, MIP1α, MCP3, 
nB CD69, IP10, mB CD86, nB CD86, mo CD86, nB DR, mB DR, mo DR, MCP1. B, B-
cell; mo, monocyte; CD4, CD4 T-cells. N, naïve phenotype; m, memory phenotype. DR, 
HLA-DR-expression.  
(B) Clusters that represent (1) patients without seroconversion but seroprotection (left), 
(2) patients without seroconversion or seroprotection (middle), and (3) patients with 
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seroconversion (right). Relative changes are indicated by changes of color code (see Fig. 
3A). Markers analyzed (top to bottom): FRAK, mo DR, IL13, CD4 IFNγ, IL9, IL5, CD4 
IL-4, IL1β, IL-4, mB CD69, sCD40L, H1N1 antibody titer, GRO, IFNα, IFNγ, IL6, 
MIP1α, MCP3, IL2, TNFα, mo CD86, nB CD86, mB CD86, nB CD69, MCP1, nB DR, 
mB DR, IP10.  B, B-cell; mo, monocyte; CD4, CD4 T-cells. N, naïve phenotype; m, 
memory phenotype. DR, HLA-DR-expression. A One-Way ANOVA applying the 
GeneSpring® software was calculated to indicate that a cytokine is differentially 
expressed in at least one of the three groups analyzed. The ANOVA analysis used the 
mean of the sum of squared deviates as an aggregate measure of variability for the 
selected group of genes, applying parametric testing for equal group sizes and 
independent samples, without post-hoc testing. PC1, PC2, and PC3 had a weight of 
54.6%, 31.9% and 13.5% respectively. 
 
FIGURE 4: Mathematical Model 
(A) Overview of the structure of the phenomenological mathematical model: IL-4-
producing T-cells and HLA-DR-expressing B-Cells activate each other in a mutual 
feedback loop that is inhibited by MMF. Antibody production is modeled in a HLA-DR-
expression-dependent manner. 
 (B-D) Dynamics of the ODE model for IL-4+T-cell frequency, HLA-DR-expression on 
naïve B-cells and H1N1 antibody HAI titer starting from patient baseline values at day 
zero for non-seroprotected patients, distinguishing between patients who seroconverted 
(black) and those who did not seroconvert (red). Simulations were performed with 
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patient-specific MMF dosage (B) and two hypothetical situations where patients receive 
no MMF (C), or a 3 g daily dose of MMF (D).  
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ptTable 1: Characteristics of transplant patients and healthy volunteers.  Transplant recipients (n=47) Healthy Volunteers (n=11) p-value 
Age, median (IQR) in years 53.4 (16) 33 (10) 
p<0.05 
Gender (m/f) 33/14 (70.2%/29.8%) 7/4 (63.6%/36.4%) 
n.s. 
Time post-transplant to immunization 
(years); median (min - max)  
4.34 (0.26 – 22.34) N/A  
Type of Vaccine 
    Standard Intramuscular  
    High-dose Intradermal 
 
26 (55%) 
21 (44.7%) 
 
11 (100%) 
 
Seroconversion (n, %) 
    Influenza A/H1N1 
    Influenza A/H3N2 
    Influenza B 
 
16 (34.0%) 
12 (25.5%) 
7 (14.9%) 
 
11 (100%) 
11 (100%) 
7 (63.6%) 
 
p<0.05 
p<0.05 
p<0.05 
Pre-vaccine Titer (GMT) 
    Influenza A/H1N1 
    Influenza A/H3N2 
    Influenza B 
 
26 
19 
16 
 
66 
55 
12 
 
0.058 
0.012 
n.s. 
Post-vaccine Titer  (GMT) 
    Influenza A/H1N1 
    Influenza A/H3N2 
    Influenza B 
 
82  
43  
29  
 
345  
206  
34 
 
p= 0.016 
p= 0.001 
n.s. 
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ptType of graft (n, %)        Kidney        Lung 
       Heart 
       Liver 
 
24 (51.1%) 
15 (31.9%) 
4 (8.5%) 
4 (8.5%) 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Immunosuppression  
(n, %, median dose/d) 
     Prednisone (median dose) 
     Tacrolimus (median trough level) 
     Cyclosporin(median trough level) 
     MMF (median dose) 
     Sirolimus(median trough level) 
 
 
35 (74.5%); 5mg/d 
36 (76.6%); 7.4μg/mL 
9 (19.1%); 78μg/mL 
34 (72.3%); 2000mg/d 
5 (10.6%); 8.2μg/mL 
 
 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
GMT Geometric Mean Titer, IQR Interquartile range, MMF mycophenolate mofetil. 
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 HLA-DR 
(MFI) 
   CD86 (MFI)    
 seroconversion  No 
seroconversion 
 seroconversion  No 
serconversion 
 
Vaccine Pre- Post- Pre- Post- Pre- Post- Pre- Post- 
All (CD20+) 203  
(125-321) 
196  
(85-287) 
1  
(1-81) 
1  
(1-1) 
276  
(145-330) 
235  
(101-419) 
105  
(1-213) 
142  
(64-274) 
Naïve 
(CD20+CD27-) 
168  
(133-296) 
246  
(108-287) 
1  
(1-41) 
1  
(1-1) 
204  
(92-289) 
211  
(87-328) 
83  
(1-151) 
59  
(3-209) 
Memory 
(CD20+CD27+) 
132  
(63-358) 
208  
(65-318) 
1  
(1-94) 
1 
 (1-36) 
409 
 (282-623) 
414 
(192-790) 
253  
(41-436) 
348  
(88-596) 
Mean fluorescence intensity (MFI) values are shown in pH1N1 overnight stimulated B-cell subsets (background subtracted).  
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ptTable 3: Receiver operating characteristic curve statistics of HLA-DR and CD86 expression on all B-cells pre-vaccination for the prediction of successful seroconversion.   
 
Variable AUC Standard 
error 
p-value 95% CI Best Cut off value 
(MFI) 
Sensitivity Specificity 
HLA-DR 0.843 .060 <0.0001 0.72-0.97 123 76.5% 84.6% 
CD86 0.700 .083 0.011 0.58-0.89 213 70.6% 76.9% 
AUC area under the curve 
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